Biogen (NasdaqGS:BIIB) recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, ...

The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...

Pharmaceutical (TADAWUL:2070) stocks saw brief relief Thursday after U.S. President Donald Trump left drug products off the list of newly announced tariffs. However, industry leaders and analysts ...

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to BIIB080, an investigational ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) today provided an update on the ongoing regulatory review of the Marketing ...

For example the Biogen Inc. (NASDAQ:BIIB) share price dropped 56% over five years. That's an unpleasant experience for long term holders. And it's not just long term holders hurting, because the stock ...

American Century Companies Inc. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 46.8% during the fourth quarter, according to its most recent filing with the Securities ...

Shares of Biogen Inc. BIIB shed 1.11% to $136.84 Monday, on what proved to be an all-around favorable trading session for the ...